Edgewise plans Phase 3 EDG-7500 trial with dosing independent of echocardiogram monitoring

• Edgewise Therapeutics plans to start its Phase 3 STRATUS-HCM trial of EDG-7500 in the fourth quarter of 2026 following favorable FDA feedback.
• The submitted protocol bases dose escalation on tolerability without echocardiograms to guide dosing, reducing monitoring requirements.
• Phase 2 data were already presented to the FDA during the end-of-phase meeting.
• The placebo-controlled trial will enroll approximately 600 adults with symptomatic hypertrophic cardiomyopathy, evaluating obstructive and nonobstructive populations independently.
• Treatment will last 24 weeks before patients enter a long-term extension; the primary endpoint assesses changes in functional capacity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edgewise Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA89800) on November 05, 2026, and is solely responsible for the information contained therein.